Nutriband Past Earnings Performance
Past criteria checks 0/6
Nutriband's earnings have been declining at an average annual rate of -20.3%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 34% per year.
Key information
-20.3%
Earnings growth rate
-14.5%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 34.0% |
Return on equity | -47.7% |
Net Margin | -315.7% |
Last Earnings Update | 30 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Nutriband makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Apr 24 | 2 | -6 | 4 | 3 |
31 Jan 24 | 2 | -5 | 4 | 2 |
31 Oct 23 | 2 | -5 | 4 | 2 |
31 Jul 23 | 2 | -5 | 4 | 1 |
30 Apr 23 | 2 | -5 | 4 | 1 |
31 Jan 23 | 2 | -4 | 4 | 1 |
31 Oct 22 | 2 | -7 | 4 | 1 |
31 Jul 22 | 2 | -7 | 5 | 1 |
30 Apr 22 | 1 | -7 | 4 | 1 |
31 Jan 22 | 1 | -6 | 4 | 0 |
31 Oct 21 | 1 | -5 | 5 | 0 |
31 Jul 21 | 1 | -3 | 4 | 0 |
30 Apr 21 | 1 | -3 | 3 | 0 |
31 Jan 21 | 1 | -3 | 3 | 0 |
31 Oct 20 | 1 | -2 | 1 | 0 |
31 Jul 20 | 0 | -2 | 1 | 0 |
30 Apr 20 | 0 | -3 | 1 | 0 |
31 Jan 20 | 0 | -3 | 2 | 0 |
31 Oct 19 | 0 | -2 | 2 | 0 |
31 Jul 19 | 1 | -2 | 2 | 0 |
30 Apr 19 | 0 | -3 | 3 | 0 |
31 Jan 19 | 0 | -3 | 3 | 0 |
31 Oct 18 | 0 | -5 | 3 | 0 |
31 Jul 18 | 0 | -5 | 2 | 0 |
30 Apr 18 | 0 | -3 | 1 | 0 |
31 Jan 18 | 0 | -3 | 0 | 0 |
31 Oct 17 | 0 | 0 | 0 | 0 |
31 Jul 17 | 0 | 0 | 0 | 0 |
30 Apr 17 | 0 | 0 | 0 | 0 |
31 Jan 17 | 0 | 0 | 0 | 0 |
Quality Earnings: 9WV is currently unprofitable.
Growing Profit Margin: 9WV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9WV is unprofitable, and losses have increased over the past 5 years at a rate of 20.3% per year.
Accelerating Growth: Unable to compare 9WV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9WV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: 9WV has a negative Return on Equity (-47.65%), as it is currently unprofitable.